Cite
HARVARD Citation
Liu, Q. et al. (2021). The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non‐small cell lung cancer: A systematic analysis and meta‐analysis based on randomized controlled trials. Journal of clinical pharmacy and therapeutics. pp. 1519-1530. [Online].